Lashify's appeal from the International Trade Commission became one of 2025's key Section 337 domestic-industry decisions.
The company was headquartered and staffed in the United States but arranged for patented eyelash-extension products to be manufactured abroad. The Federal Circuit reviewed how that business model fits the ITC's domestic-industry requirement.
For brands that design, market, and coordinate products domestically while manufacturing overseas, the decision is commercially important. Import remedies should not turn only on factory location.
The case belongs in IPDispatch's enforcement and platforms lane because it ties patent rights to real-world supply chains, consumer goods, and exclusion-order strategy.